Potential of this IL‐6 inhibitor in reduction of CRP and MACE rates amongst patients with cardiovascular disease, chronic kidney disease and baseline hs‐CRP levels of > 2.0 mg/L, is currently being tested in the ZEUS trial; results of which are highly anticipated [83]. This evidence concerns the gene IL6 and cardiovascular disorder.